Programmed cell death protein 1 (PD-1) and its ligand PD-L1 have displayed remarkable efficacy in patients with non-small-cell lung cancer, advanced melanoma, bladder cancer, or metastatic renal-cell carcinoma [4–7]. Here, PDCD1 is linked to urinary bladder cancer.